Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
OwnerStephen R. Hansoninventor
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
Claims66
A method for treating a subject to inhibit a vaso-occlusive event comprising administering to the subject an MPL pathway inhibitory agent in an amount effective to reduce platelet count in the subject to a low normal level.
The method of claim 25, wherein the effective amount is in the range of 0.001 mg/kg/day to 30 mg/kg/day.
A sustained release device comprising an MPL inhibitory agent that reduces platelet count in a subject, wherein the agent is released for at least 7 days.
A pharmaceutical preparation comprising
- an amount of an agent that inhibits signal transduction from an MPL receptor effective to reduce platelet count, and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- an amount of an agent that binds to an MPL receptor effective to reduce platelet count, and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- an amount of an agent that binds to a thrombopoietin molecule effective to reduce platelet count, and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- an amount of an agent that binds to an intracellular tyrosine kinase that modulates signal transduction from an MPL receptor effective to reduce platelet count, and
- a pharmaceutically acceptable carrier.
A pharmaceutical preparation comprising
- an amount of an agent that inhibits binding of a thrombopoietin molecule to an MPL receptor effective to reduce platelet count, and
- a pharmaceutically acceptable carrier.
The method of 34, wherein the an agent for treating vascular disorder or vascular complication is selected from the group consisting of anti-inflammatory agents, antithrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein IIb/IIIa receptor inhibitors, agents that binds to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules, calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, and angiotensin system inhibitors.
A method for treating a subject having above normal platelet count comprising administering to the subject in need of such treatment an MPL pathway inhibitory agent in an amount effective to reduce platelet count.
Dependencies are inferred from the claim text.